Twinn Health claims to be advancing longevity and preventive healthcare thanks to a $500 million venture capital fund from Saudi Aramco.
Using MRI technology in the medical field is nothing new. Developments in AI have made it easier to identify specific disorders in MRI scans. Their wider applicability in disease detection and lengthening lifespan is still in its infancy.
“Usually, when you do an MRI today, it’s one MRI scan for one single diagnosis,” Wareed Alenaini, founder and CEO of Twinn Health, explains in an interview with Longevity Technology, citing kidney stones as an example.
“You do the MRI. The doctor looks at the kidney stones, writes the report, and then the scan data gets archived, and will probably never be checked again,” Alenaini continues. “That’s where Twinn comes in: we’re extracting additional insights from MRI scans that may not have been the primary focus of the physician.”
By combining MRI and AI, Twinn Health hopes to usher in a new era in healthcare by identifying and treating age-related disorders at an early stage. The company's aggressive strategy calls for addressing liver disease and age-related weakness.
“We’re using technology to make chronic disease prevention scalable,” Alenaini told the website, which is published by First Longevity and backed by Marco Polo Securities.
Alenaini, a Saudi native with a doctorate in bioimaging from Imperial College London, developed the idea for Twinn Health while researching the patterns of the human body in MRI pictures and their relationship to illness progression.
Twinn's primary area of interest is metabolic disease, which is a trifecta of diabetes, high blood pressure, and obesity. Because of how susceptible these disorders make people are to serious health problems like coronary heart disease and stroke. Twinn's AI platform examines MRI pictures for potentially dangerous hidden fatty deposits surrounding organs, which are an important sign of heart disease even in healthy people.
Alenaini asserted initial tests had produced encouraging findings, with a 95% accuracy rate in 2021, which were later corroborated by actual data and NHS doctors in the UK in 2022.
Alenaini claims that Twinn's patented artificial intelligence algorithm can predict metabolic abnormalities up to a half-decade in advance.
Alenaini told Longevity Technology that the company aims to hold four additional patents, address three more conditions, and amass a million data points to showcase their scalability and accessibility.
Twinn's idea is completely in line with the growing global interest in longevity.
“As the longevity field evolves and with the emergence of more healthy longevity clinics, we see ourselves as the most accurate diagnostic platform that can support this,” she said. “We are currently focusing on getting FDA approval for the American market, but our next focus will be the Middle East because we have seen a very significant push into longevity in that part of the world.”
Future disease targets include age-related frailty (sarcopenia) and liver disease.
Twinn Health is currently looking for more funding as it aims to expand into more illness indications. Early funding efforts were concentrated on metabolic disease, but the company is now prepared to expand into additional disease pathways, further solidifying its dedication to longevity.